The clinical utility of PSMA SP2 0-AG14 monoclonal antibody in the detection of primary and peripheral blood metastatic prostate cancer
Other Title(s)
الفائدة الطبية للجسم المضاد الأحادي PSMA Sp2 0-A في الكشف عن سرطان البروستاتو انتشار في الدم
Dissertant
Thesis advisor
Isawi, Tamir
Farraj, Muhammad A.
Comitee Members
Hammudah, Wail
Abu Arafah, Wail
University
Birzeit University
Faculty
Faculty of Science
Department
Department Nutrition and Dietetics
University Country
Palestine (West Bank)
Degree
Master
Degree Date
2005
English Abstract
Prostate-specific membrane antigen (PSMA) is a membrane-bound glycoprotein highly restricted to prostatic epithelial cells.
It is expressed by virtually all prostate cancers and its expression is further increased in poorly differentiated, metastatic, and hormone-refractory carcinomas. Over the past two decades, monoclonal antibody technology has had an increasing impact on clinical diagnostic and therapeutic options, and this is true in the realm of managing prostate cancer. Given its membrane-bound character, PSMA is an ideal sentinel molecule for use in targeting prostatic cancer cells.
Monoclonal antibodies specific for PSMA are available, beginning with the antibody 7E11-C5.3 which originally defined PSMA and which has been developed for use in cancer detection via immunoscintigraphy in the ProstaScint scan.
The monoclonal antibody Sp2/0-Ag14 is a recently developed primary IgG2bκ mouse anti-human PSMA. In the present study the immunohistochemical properties of anti-PSMA Sp2/0-Ag14 clone with primary prostate cancer tissue and its utility in the detection of hematogenous prostate cancer cell dissemination have been examined. The anti-PSMA Sp2 / 0-Ag14 clone had consistent PSMA immunoreactivity with prostate adenocarcinoma with the greatest extent and intensity observed in the highest tumor grades.
The antibody also detected circulating prostate cancer cells in all stage IV patients examined with no ectopic signals. This study demonstrates the utility of anti-PSMA Sp2 / 0-Ag14 monoclonal antibody in the early detection of localized prostate cancer and in the detection of occult peripheral blood metastasis after cure treatment such as radical prostatectomy allowing it to be useful as a tissue-based prostate carcinoma marker and as a peripheral blood metastatic surveillance marker during or after therapy.
Main Subjects
Topics
No. of Pages
46
Table of Contents
Table of contents.
Abstract.
Chapter one : Introduction.
Chapter two : Materials and methods.
Chapter three : Results.
Chapter four : Discussion.
Chapter five : Conclusion.
References.
American Psychological Association (APA)
Hazboun, Nadir Anton. (2005). The clinical utility of PSMA SP2 0-AG14 monoclonal antibody in the detection of primary and peripheral blood metastatic prostate cancer. (Master's theses Theses and Dissertations Master). Birzeit University, Palestine (West Bank)
https://search.emarefa.net/detail/BIM-303717
Modern Language Association (MLA)
Hazboun, Nadir Anton. The clinical utility of PSMA SP2 0-AG14 monoclonal antibody in the detection of primary and peripheral blood metastatic prostate cancer. (Master's theses Theses and Dissertations Master). Birzeit University. (2005).
https://search.emarefa.net/detail/BIM-303717
American Medical Association (AMA)
Hazboun, Nadir Anton. (2005). The clinical utility of PSMA SP2 0-AG14 monoclonal antibody in the detection of primary and peripheral blood metastatic prostate cancer. (Master's theses Theses and Dissertations Master). Birzeit University, Palestine (West Bank)
https://search.emarefa.net/detail/BIM-303717
Language
English
Data Type
Arab Theses
Record ID
BIM-303717
